Actively Recruiting
Co-administration of CART22-65s and huCART19 for B-ALL
Led by Stephan Grupp MD PhD · Updated on 2026-03-27
93
Participants Needed
1
Research Sites
335 weeks
Total Duration
On this page
Sponsors
S
Stephan Grupp MD PhD
Lead Sponsor
U
University of Pennsylvania
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
CONDITIONS
Official Title
Co-administration of CART22-65s and huCART19 for B-ALL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form
- Diagnosis of CD19-positive and/or CD22-positive Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- For Cohort A: relapsed or refractory ALL/LLy
- For Cohort B: poor response to prior B cell targeted engineered cell therapy
- History of Central Nervous System 3 disease allowed if responsive to therapy
- Documentation of CD19 and/or CD22 tumor expression by flow cytometry at last detectable disease
- Age between 0 and 29 years
- Adequate organ function
- Performance status with Lanksy or Karnofsky score 50 or higher
- Agreement to use acceptable birth control methods if of reproductive potential
You will not qualify if you...
- Active hepatitis B or hepatitis C infection
- HIV infection
- Active acute or chronic Graft Versus Host Disease requiring systemic therapy
- Use of systemic steroids or immunosuppression at time of cell infusion or collection, or conditions likely to require such therapy during these times
- Progressive central nervous system disease or CNS parenchymal lesions increasing CNS toxicity risk
- Pregnant or nursing women
- Uncontrolled active infections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
C
CART Nurse Navigator
CONTACT
M
Melissa S. Varghese, M.S.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here